Research Paper Volume 13, Issue 15 pp 19475—19485
FK506 binding protein 10: a key actor of collagen crosslinking in clear cell renal cell carcinoma
- 1 Department of Urology Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- 2 Department of Oncology Radiotherapy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
- 3 Department of Gynecological Radiotherapy, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China
- 4 Department of Urology Surgery, The First Hospital of Harbin, Harbin, China
Received: May 27, 2021 Accepted: July 10, 2021 Published: August 13, 2021https://doi.org/10.18632/aging.203359
How to Cite
Copyright: © 2021 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Clear cell renal cell carcinoma (ccRCC) is the most common type of malignant tumor in the kidney. With numbers of patients whose physical condition or tumor stage not suitable for radical surgery, they only have a narrow choice of using VEGF/mTOR targeted drugs to control their tumors, but ccRCC often shows resistance to these drugs. Therefore, identifying a new therapeutic target is of urgent necessity. In this study, for the first time, we concluded from bioinformatics analyses and in vitro research that FK506 binding protein 10 (FKBP10), together with its molecular partner Lysyl hydroxylase 2 (LH2/PLOD2), participate in the process of type I collagen synthesis in ccRCC via regulating crosslinking of pro-collagen chains. Our findings may provide a potential therapeutic target to treat ccRCC in the future.